FIELD: medicine, pharmaceutics.
SUBSTANCE: solid dosage form contains valsartan, amlodipine, hydrochlorothiazide and pharmaceutically acceptable additives and is presented in the form of a two-layer tablet. Quantitative proportions of valsartan, amlodipine and hydrochlorothiazide are selected from the following: 160 mg/12.5 mg/5 mg, 160 mg/12.5 mg/10 mg, 160 mg/25 mg/10 mg, 160 mg/25 mg/5 mg and 320 mg/25 mg/10 mg. Preferentially, amlodipine is used in the form of amlodipine besylate. The two-layer tablet can contain valsartan and hydrochlorothiazide in the first layer, and amlodipine in the second layer, or valsartan in the first layer, and amlodipine and hydrochlorothiazide in the second layer. Also, there are described methods for making a two-layer tablet.
EFFECT: two-layer tablet under the invention with the fixed combination of valsartan, amlodipine and hydrochlorothiazide have the biological properties equivalent to those of a free combination of said medical agents.
17 cl, 11 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
GALENIC FORMULATIONS OF ALISKIREN | 2008 |
|
RU2483718C2 |
DOUBLE-ACTION PHARMACEUTICAL COMPOSITIONS OF SUBMOLECULAR STRUCTURE OF ANGIOTENSIN RECEPTOR BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR | 2008 |
|
RU2493844C2 |
GALENA COMPOSITION OF ALISKIREN AND HYDROCHLOROTHIAZIDE | 2007 |
|
RU2491058C2 |
COFORMULATED DRUG FOR CARDIOVASCULAR DISEASES BASED ON CHRONOTHERAPY THERAPY | 2007 |
|
RU2464014C2 |
SOLID MEDICATION OF OLMESARTAN MEDOXOMIL AND AMLODIPINE | 2007 |
|
RU2423975C2 |
COMBINATION OF ORGANIC COMPOUNDS | 2003 |
|
RU2324482C2 |
PHARMACEUTICAL COMBINED COMPOSITION | 2016 |
|
RU2736942C2 |
STABLE PHARMACEUTICAL PREPARATION CONTAINING AMLODIPINE BENZYLATE AND ATENOLOL | 1998 |
|
RU2188636C2 |
MULTI-LAYERED TABLET, CONTAINING EFFERVESCENT LAYER | 2010 |
|
RU2547562C2 |
NEW COMPOSITION | 2006 |
|
RU2821230C2 |
Authors
Dates
2012-05-10—Published
2007-06-26—Filed